Article ; Online: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.
2024 Volume 263, Issue 2, Page(s) 190–202
Abstract: Cancer immunotherapy has transformed the clinical approach to patients with malignancies, as profound benefits can be seen in a subset of patients. To identify this subset, biomarker analyses increasingly focus on phenotypic and functional evaluation of ... ...
| Abstract | Cancer immunotherapy has transformed the clinical approach to patients with malignancies, as profound benefits can be seen in a subset of patients. To identify this subset, biomarker analyses increasingly focus on phenotypic and functional evaluation of the tumor microenvironment to determine if density, spatial distribution, and cellular composition of immune cell infiltrates can provide prognostic and/or predictive information. Attempts have been made to develop standardized methods to evaluate immune infiltrates in the routine assessment of certain tumor types; however, broad adoption of this approach in clinical decision-making is still missing. We developed approaches to categorize solid tumors into 'desert', 'excluded', and 'inflamed' types according to the spatial distribution of CD8+ immune effector cells to determine the prognostic and/or predictive implications of such labels. To overcome the limitations of this subjective approach, we incrementally developed four automated analysis pipelines of increasing granularity and complexity for density and pattern assessment of immune effector cells. We show that categorization based on 'manual' observation is predictive for clinical benefit from anti-programmed death ligand 1 therapy in two large cohorts of patients with non-small cell lung cancer or triple-negative breast cancer. For the automated analysis we demonstrate that a combined approach outperforms individual pipelines and successfully relates spatial features to pathologist-based readouts and the patient's response to therapy. Our findings suggest that tumor immunophenotype generated by automated analysis pipelines should be evaluated further as potential predictive biomarkers for cancer immunotherapy. © 2024 The Pathological Society of Great Britain and Ireland. |
|---|---|
| MeSH term(s) | Humans ; Immunophenotyping/methods ; Tumor Microenvironment/immunology ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Lymphocytes, Tumor-Infiltrating/immunology ; Biomarkers, Tumor ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/therapy ; Female ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/therapy ; CD8-Positive T-Lymphocytes/immunology ; Predictive Value of Tests |
| Chemical Substances | B7-H1 Antigen ; Biomarkers, Tumor ; CD274 protein, human ; Immune Checkpoint Inhibitors |
| Language | English |
| Publishing date | 2024-03-25 |
| Publishing country | England |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 3119-7 |
| ISSN | 1096-9896 ; 0022-3417 |
| ISSN (online) | 1096-9896 |
| ISSN | 0022-3417 |
| DOI | 10.1002/path.6274 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ud II Zs.12: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.